Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 4, 2009, to announce its financial and operating results for the second quarter ended June 30, 2009. While the 8-K itself does not contain the detailed results, it formally submits the press release detailing these outcomes as an exhibit. Investors should refer to the attached press release (Exhibit 99.1) for specifics on the company's performance during the quarter. This filing serves as the official notification mechanism for the market regarding Regeneron's latest financial and operational updates. The attached press release would typically cover key metrics such as revenue, earnings per share, research and development progress, and any significant corporate developments. Investors are encouraged to review this press release to understand the company's current financial health and strategic direction.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) filed a Form 8-K on August 4, 2009.
- 2The filing's primary purpose is to announce the company's financial and operating results for the second quarter ended June 30, 2009.
- 3The press release containing the detailed results for the quarter is furnished as Exhibit 99.1 to the 8-K.
- 4This report follows the requirements of Item 2.02 (Results of Operations and Financial Condition) of Form 8-K.
- 5Investors need to consult the attached press release for the specific financial figures and operational updates.
- 6The report indicates the event date for the announced results was August 3, 2009.